• AIMS: The invention is to analyze metabolic condition, especially in oxygen consumption and energy production in the adipose tissues of human (Patent: JP 3848818).
• PROBLEM TO BE SOLVED: To provide an instrument and method for analyzing the metabolism condition of a living body which is constructed in such a manner that it can measure the metabolism condition of a living body correctly and easily, and a recording medium.
• SOLUTION: A metabolism condition analyzer is provided with an input means for inputting information about the body of a subject, a control means for processing this information and an output means for outputting results of the processing. The information consists of name, age, sex, race, height, weight, bioelectric resistance value and the date and time of measurement. A data file consisting the control means stores evaluation data of a metabolic condition which is previously determined by medical judgment based on a combination of an internal respiration index and oxygen consumption and energy production in adipose tissues. These are computed by calculating the value obtained by subtracting one from a body density calculated from the height, weight of the subject and the bioelectric resistance value and then multiplying the value. Welcome to your investment or co-operation.

• AIMS: This invention is to support the doctor’s prescription for diabetes and metabolic syndrome, especially in Japanese Clinic (Patent: JP 4176438).
• PROBLEM TO BE SOLVED: To perform a further efficient preparation by providing information for original medicine and generic medicine in the preparation.
• SOLUTION: The medicine price, pharmacologic effect and the like of each of original medicine and generic medicine are preliminarily recorded in a medicine database, and a generic medicine corresponding to the original medicine inputted by a doctor is automatically retrieved and displayed on a display. When the total number of the inputted medicine exceeds a number determined by insurance medical care, the generic medicine is retrieved so that the drug price of the group of the same usage is a prescribed amount or less. Welcome to your investment or co-operation.

• Dr. Katsunori Nonogaki has developed the novel ultrasound irradiation device, which can improve the autonomic nervous system activity and peripheral circulation. In addition, the ultrasoud device can improve hypertension and hyperglycemia within 20 min in subjects with drug-resistant hypertension and diabetes. Our initial device was approved in Japan (226AIBZX00028000). This device will be avaliable for the treatment of 1) muscle pain, 2) the autonomic neural dysfunction and stress-related disorders, 3) hypertention, and 4) diabetes. Moreover, the device will be usefull for your healthy life and aging care.

Our aims are to export the device internationally. We seek the investment and international business partners.

• Strong points
• Anemia is a very prevalent disease. Nevertheless, an effective therapy is yet to be discovered. Erythropoietin is effective only for those with renal dysfunction. We have found that inhibition of an enzyme for epigenetic regulation results in a prominent increase of erythropoiesis, pointing to a new target for anemia therapy. We have also generated a new, cell-based assay system for the enzymatic activity and carried out small molecule screening.
• Collaboration with industry partners
• We are seeking a collaboration to accelerate the development of new anemia drugs based on these findings. Together we will advance the development of the candidate molecules currently identified as well as conduct further screening of larger chemical space for better candidates and/or for drug repositioning.

• Primary aldosteronism is a leading cause of secondary hypertension accounting for approximately 10 % of hypertensive patients; 4 million patients potentially exist in Japan. We aim to optimize the method of ablating aldosterone producing adenoma using newly developed bipolar radiofrequency ablation system with 300-400kHz high-frequency current and electric power of 40W (Celon Prosurge Applicator), and establish a less invasive interventional radiological treatment of primary aldosteronism.

Collaboration with medical equipment manufacture and universities are expected to develop new devices enabling ablation of aldosterone producing adenoma. Flexible guide-wire-type ablation system and rapid aldosterone assay system should be co-developed to tread aldosterone producing microadenoma which is difficult to detect due to its small diameter of less than 5mm.